Singh Kaalindi, Katoch Kalpana, Pal Kapil M, Negi Ratti R
Radiotherapy, Shri Lal Bahadur Shastri Government Medical College and Hospital, Mandi, IND.
Pediatrics, Rohilkhand Medical College, Bareilly, IND.
Cureus. 2024 Feb 27;16(2):e55112. doi: 10.7759/cureus.55112. eCollection 2024 Feb.
Breast cancer is the most common malignancy among women worldwide. This study was conducted to determine the quality of life (QOL) outcomes among breast cancer patients in the sub-Himalayan region and, secondly, to identify factors affecting them.
The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and BR-45 questionnaires in English and Hindi translations were used. The BR-45 Hindi translation was obtained using the forward-backward translation method. To check internal consistency and validity, Cronbach's alpha was employed. EORTC scoring manuals were used to score the questionnaires. The analysis of variance test was used to determine the impact of different treatment and sociodemographic factors on QOL domains.
The English and Hindi translations had Cronbach's alpha values of 0.949 and 0.950, respectively, suggesting that the data gathered were reliable. The mean score for global health status was 64.4 ± 29.7, the functional scale (FS) of QLQ_C30 was 76.9 ± 21.5, the FS of BR45 was 64.6 ± 24.1, the symptom scale (SS) of QLQ_C30 was 20.3 ± 19.2, and the SS of BR45 was 22.5 ± 19.1. Factors adversely affecting global health status included younger age, pre/perimenopausal status, and ongoing chemotherapy. Functional scales were significantly affected by marital status and earlier stages of the disease. Symptom scales were adversely affected by ongoing chemotherapy, an earlier stage of the disease, and a duration of treatment of less than six months.
Tailoring treatment to reduce radiotherapy, surgery, and systemic therapy-related side effects may improve QOL. Counselling and social support groups may help patients cope with the burden of family and societal roles.
乳腺癌是全球女性中最常见的恶性肿瘤。本研究旨在确定喜马拉雅地区乳腺癌患者的生活质量(QOL)结果,其次,确定影响这些结果的因素。
使用欧洲癌症研究与治疗组织(EORTC)的QLQ-C30和BR-45问卷的英文和印地语译本。BR-45的印地语译本采用前后翻译法获得。为检查内部一致性和有效性,采用了Cronbach's α系数。使用EORTC评分手册对问卷进行评分。采用方差分析测试来确定不同治疗和社会人口学因素对QOL领域的影响。
英文和印地语译本的Cronbach's α系数分别为0.949和0.950,表明所收集的数据可靠。全球健康状况的平均得分为64.4±29.7,QLQ_C30的功能量表(FS)为76.9±21.5,BR45的FS为64.6±24.1,QLQ_C30的症状量表(SS)为20.3±19.2,BR45的SS为22.5±19.1。对全球健康状况产生不利影响的因素包括年龄较小、绝经前/围绝经期状态以及正在进行化疗。功能量表受婚姻状况和疾病早期阶段的显著影响。症状量表受到正在进行的化疗、疾病早期阶段以及治疗时间少于六个月的不利影响。
调整治疗以减少放疗、手术和全身治疗相关的副作用可能会改善生活质量。咨询和社会支持团体可能有助于患者应对家庭和社会角色的负担。